News Archives - Page 173 of 750

TuesdayOct 31, 2023 10:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Taking Part in the Trucking Industry’s Ongoing Paradigm Shift with Its Fr8App Platform

Lexaria, a global innovator in drug delivery platforms, just announced an exclusive license to SulfoSyn Limited to use its patented DehydraTECH(TM) technology Lexaria will also perform specific DehydraTECH-related manufacturing operations on SulfoSyn’s behalf for an initial term of 2 years The license agreement adds to Lexaria’s growing list, which, as of the last two years, includes BevNology LLC, Premier Wellness Science Co. Ltd., and Dehydr8, LLC, among others It highlights the superiority of Lexaria’s technology, as further compounded by the 37 patents granted so far Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its latest…

TuesdayOct 31, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows List of Licensed Partners Following Exclusive Collaboration and License Agreement with SulfoSyn

MondayOct 30, 2023 3:00 pm

Diamond Lake Minerals Inc. (DLMI) Welcomes Brian J. Esposito As Company CEO In Addition To Seven New Strategic Advisors

Brian J. Esposito, founder and CEO of Esposito Intellectual Enterprises, LLC., boasts 20 years of experience and a proven track record of driving growth and innovation Increase in Strong Advisory Board: Agnes Budzyn, Anthony Scaramucci, Larry Namer, Michael J. Malik Sr., Andrew Fromm, Brandon Fugal, and Raul Leal Newest board additions bring the company closer to its ultimate vision and further strengthen its competitive advantages, including innovative technology, a diverse portfolio, and highly experienced leadership Diamond Lake Minerals (OTC: DLMI), a company positioning itself as a rapidly developing leader in the digital asset and security token space, recently announced the…

MondayOct 30, 2023 2:30 pm

Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0) Eyes Growth on New Pricing for SekurVPN Packages, Launch of Communication Suite in German Language

Sekur Private Data has reported increasing new subscriber signups for SekurVPN, the world’s first non-big-tech-powered, Swiss-hosted privacy-focused VPN solution launched in April So far, SekurVPN’s sales have surpassed its projections, and the company is now expecting solid growth for SekurVPN for the foreseeable future The company recently announced plans to increase its prices for SekurVPN by 30%, following careful considerations and consultations with the digital marketing team Even with the new prices, SekurVPN is still the most affordable privacy VPN in the market, according to CEO Alain Ghiai Sekur Private Data recently announced plans to launch its Swiss-hosted communications suite,…

MondayOct 30, 2023 11:15 am

Mountain Top Properties Inc. (MTPP) Is ‘One to Watch’

Mountain Top Properties has issued 250,108,363 shares of common stock as of August 2023 The company will consider selling securities to fund future operations Mountain Top Capital Fund I has a target to raise $75 million to fund its Hamptons projects The company targets minimum ROI of 20% to 30% per transaction Mountain Top Properties (OTC: MTPP) is a diversified real estate holding company that acquires, sells and operates assets through its wholly owned subsidiaries and limited partnerships. The company specializes in property management, property technology (“PropTech”) and real estate redevelopment. Mountain Top Properties was incorporated in 1990 and is…

MondayOct 30, 2023 10:30 am

SenesTech Inc. (NASDAQ: SNES) Geometrically Increases its Addressable Market with the Addition of Evolve(TM) Soft Bait to its Portfolio

SenesTech, a rodent fertility control expert, just announced the launch of its Evolve(TM) Soft Bait, representing an innovative, patent pending, minimum risk alternative treatment to reduce fertility in rats This product adds to the company’s growing line of pest control solutions, such as ContraPest(R), a highly palatable liquid contraceptive bait SenesTech’s management has lauded this milestone, noting how the product, with its non-liquid form, will dramatically increase its addressable market The company plans to market it to professionals as well as directly to consumers through e-commerce and big-box stores SenesTech (NASDAQ: SNES), a rodent fertility control expert and the inventor…

MondayOct 30, 2023 9:45 am

Clene Inc. (NASDAQ: CLNN) Reports Improved Survival Status in ALS Patients Treated with CNM-Au8(R) on Follow-Up Analysis; Announces Peer-Reviewed Study

Clene is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases like ALS In 2019, Clene’s drug candidate, CNM-Au8(R), was selected for the HEALEY ALS Platform Trial, with enrollment commencing in the summer of 2020 Over the years since, Clene has consistently released additional data from the Trial, most recently reporting significant long-term survival improvement among patients treated with CNM-Au8 compared to PRO-ACT historical controls The company also announced the publication of a peer-reviewed study in the nanotechnology-focused journal Small; the study describes CNM-Au8’s mechanism of action Clene received a $45.1…

MondayOct 30, 2023 9:00 am

Longeveron Inc. (NASDAQ: LGVN) Validates Safety and Therapeutic Potential of its Lomecel-B(TM) Lead Investigational Product in its CLEAR MIND Phase 2a Clinical Trial

Longeveron, a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions, reported positive top-line results from its CLEAR MIND Phase 2a human clinical trial The study, which explored Lomecel-B(TM)’s effects on mild Alzheimer’s disease, met the primary endpoint of safety on statistical and medical assessment Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions, just announced positive top-line results from its CLEAR MIND Phase 2a clinical trial for treating mild Alzheimer’s disease. Most notably, the primary endpoint of safety was met based on statistical and medical assessment, with only one Serious Adverse…

FridayOct 27, 2023 9:45 am

PaxMedica Inc.’s (NASDAQ: PXMD) CEO and Corporate Communications Chief Discuss Regulatory Strategy for Lead Drug Candidate and Future Plans in Recent Bell2Bell Podcast Interview

PaxMedica Chairman and CEO Howard Weisman participated in a recent Bell2Bell Podcast interview and was joined by Buzz Woods from Corporate Communications Weisman discussed the company’s strategy to seek FDA approval for Suramin as a treatment for Human African Trypanosomiasis (“HAT”) and plans for 2024 If PaxMedica is successful in getting approval in HAT, the company believes that could lead to the receipt of a Priority Review Voucher (“PRV”) The company hopes to monetize the PRV to raise funds that will support research and future trials investigating Suramin as a treatment for Autism Spectrum Disorder PaxMedica hopes to file an…

FridayOct 27, 2023 9:00 am

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Showcase Its Boutique End-to-End CDMO Services at the Premier CPHI Barcelona Event

Scinai will exhibit at the upcoming CPHI Barcelona event, showcasing its CDMO services The company expanded into the CDMO business earlier this year, operating under the banner Scinai Bioservices Scinai’s boutique end-to-end CDMO business division serves pharmaceutical, biotech, and alternative protein food tech companies with pilot and clinical process development and cGMP manufacturing Scinai intends to serve small biotech companies who require CDMO services with superior value compared to large, multinational CDMO companies Scinai will also exhibit at the upcoming BIO-Europe conference in Munich Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products,…

Site Search

Company Search

Category: News